VanEck Pharmaceutical ETF
102 hedge funds and large institutions have $392M invested in VanEck Pharmaceutical ETF in 2023 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 29 reducing their positions, and 18 closing their positions.
207% more call options, than puts
Call options by funds: $780K | Put options by funds: $254K
21% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 29
11.21% more ownership
Funds ownership: 96.14% → 107.35% (+11%)
10% more capital invested
Capital invested by funds: $358M → $392M (+$34.7M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 106 → 102 (-4)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$23.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$18.5M |
| 3 |
PCIA
Prime Capital Investment Advisors
Overland Park,
Kansas
|
+$11.5M |
| 4 |
MIM
Miller Investment Management
West Conshohocken,
Pennsylvania
|
+$11.1M |
| 5 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$8.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$37.9M |
| 2 |
HF
HRT Financial
New York
|
-$5.21M |
| 3 |
Morgan Stanley
New York
|
-$2.78M |
| 4 |
SIM
Seaview Investment Managers
Miami,
Florida
|
-$2.04M |
| 5 |
AC
ASB Consultores
Aventura,
Florida
|
-$1.88M |
PPH Hedge Fund Activity: Q2 2023 in Review
102 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2023, worth a combined $392M — up 9.7% from $358M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of PPH and 14 opened new positions — a net loss of 4 holders — while 29 trimmed existing stakes and 35 added.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $23.5M. The largest seller was Goldman Sachs, cutting an estimated $37.9M.
- 102 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2023, down from 106 in Q1 2023.
- Funds reported $392M of VanEck Pharmaceutical ETF stock for Q2 2023, up 9.7% quarter-over-quarter.
- 14 funds opened new VanEck Pharmaceutical ETF positions in Q2 2023 and 18 closed out, a net change of -4 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q2 2023 was BNP Paribas Financial Markets, an estimated $23.5M added.
- The largest VanEck Pharmaceutical ETF seller in Q2 2023 was Goldman Sachs, an estimated $37.9M sold.
Based on aggregated 13F filings for Q2 2023.